Solid Biosciences (SLDB)
NASDAQ:SLDB
Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$8.63
$0.18(4.59%)
At close: 4:00 PM EST
$8.63
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$3.79 - $8.87
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.72M
Market Cap
$820.09M
Enterprise Value$292.45M
Total Cash (Recent Filing)$381.32M
Total Debt (Recent Filing)$20.67M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 17, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding98,449,610
10 Day Avg. Volume2,925,807
30 Day Avg. Volume1,724,204
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-374.46
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$16.75Price Target Upside94.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing Revenue StreamThe majority-owned Solid Biologics unit produces recurring, fee-for-service revenue from viral vector development and GMP manufacturing. That service business diversifies cash generation away from binary clinical outcomes, provides steady customer demand, and supports operational continuity while therapeutics remain pre-commercial.
Low Financial LeverageModest absolute debt and a low debt-to-equity ratio reduce fixed financing obligations and lower near-term solvency risk. This structural balance-sheet strength preserves strategic optionality for R&D investment or contract-manufacturing capacity expansion without substantial interest-driven cash drain.
Authorized-share Increase Expands Financing OptionsDoubling authorized shares is a structural corporate action that materially increases the company's ability to raise capital or pursue transactions via equity issuance. Over the medium term, this enhances the company's flexibility to fund clinical programs, manufacturing scale-up, or strategic partnerships when needed.
Bears Say
High Cash Burn And Negative Free Cash FlowPersistent, very large negative free cash flow creates structural funding pressure; operating cash generation does not cover expenses and the company must repeatedly access capital markets or partners to fund operations. This elevates dilution and execution risk absent sustained cash inflows.
Minimal Therapeutic Revenue And Widening LossesAs a clinical-stage developer, the company generates essentially no product revenue while incurring growing operating losses. The absence of an improving profitability trajectory means margins and long-term self-funding capacity remain weak until regulatory approvals and commercialization occur, if at all.
Dependence On External Financing And Equity VolatilityVolatile equity and historical reliance on financings imply the company must repeatedly tap capital markets, creating sustained dilution risk and planning uncertainty. This structural dependence constrains long-term capital allocation flexibility and increases investor exposure to financing cycles.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.79 and its highest was $8.87 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $820.09M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 56 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on May 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.429 by -$0.091.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.46.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 98,449,610 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.429. Following the earnings report the stock price went down -4.404%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.75 (94.09% Upside)
$16.75 (94.09% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.13%
12-Months-Change
Fundamentals
Return on Equity
-74.45%
Trailing 12-Months
Asset Growth
22.97%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$16.75
▲(94.09% Upside)
Technical Analysis
Ownership Overview
13.16% Insiders
9.50% Mutual Funds
65.03% Other Institutional Investors
4.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---